Remibrutinib Shows Promise in Treating Chronic Spontaneous Urticaria
Recent clinical trials have highlighted the potential of remibrutinib as a treatment for chronic spontaneous urticaria (CSU). This novel therapy targets Bruton tyrosine kinase (BTK), a key player in the…